Keeping with the trend of high-value biopharma deals, the second quarter of 2019 logged another eight partnerships worth $1 billion or more, with Gilead Sciences Inc. a party to three of them.
Keeping with the trend of high-value biopharma deals, the second quarter of 2019 logged another eight partnerships worth $1 billion or more, with Gilead Sciences Inc. a party to three of them.
Keeping with the trend of high-value biopharma deals, the second quarter of 2019 logged another eight partnerships worth $1 billion or more, with Gilead Sciences Inc. a party to three of them.
Public hearings, drafted recommendations and new legislation are all recent efforts by pain and addiction stakeholders, including government and industry, to effectively change standards of practice that have abandoned patients for years.
In a culture that dismisses pain and addiction as laziness or a moral failure, where drug developers find few economic incentives and patients hit treatment access roadblocks, those directly impacted are telling their stories to spur meaningful action.
PHILADELPHIA - While amounts raised through seed and series A venture capital rounds in 2018 have towered above previous years, indicating a growing interest in investing early, the money does not address a researcher's need to fund science at an even earlier stage, sometimes at the very beginnings of an idea.
PHILADELPHIA – Developing new therapeutics for small patient populations is a challenging endeavor for researchers, but a collective 30 million patients in the U.S. with an estimated 7,000 rare diseases continue to wait for treatments.
PHILADELPHIA – Record new molecular entity approvals, record venture capital financings, record Chinese investments and record research-stage acquisitions all leave biopharma executives attending the Biotechnology Innovation Organization's international convention with one pressing question.
Venture capital investments in biopharma companies are on track this year to beat out 2017 and every year prior, although the projected amount raised and the number completed appear to be shy of the record-breaking year of 2018.
Venture capital investments in biopharma companies are on track this year to beat out 2017 and every year prior, although the projected amount raised and the number completed appear to be shy of the record-breaking year of 2018.
